Related Experiment Videos
Estrogen receptor protein in visceral metastases from breast carcinoma
Abstract:
Estrogen receptor protein assays were done on 1,243 tissue specimens, 34 of which represented metastases from primary breast carcinoma to parenchyma of liver, lung or brain. Eight of these specimens contained significant amounts of estrogen receptor protein. Most (4 of 5 evaluable cases) of the ERP-positive patients responded to endocrine ablation, as compared with 13 percent (2 of 16 evaluable cases) of the ERP-negative patients. We conclude that biopsy of liver and lung metastases may be useful in some circumstances and that endocrine manipulation frequently provides palliation when these metastases are ERP-positive.
Insights
Estrogen receptor protein (ERP) assays on breast cancer metastases revealed that ERP-positive tumors often respond to endocrine ablation, offering a palliative treatment option.
Area of Science:
- Oncology
- Endocrinology
- Pathology
Background:
- Estrogen receptor protein (ERP) status is crucial for breast cancer treatment decisions.
- Metastatic breast cancer can spread to organs like the liver, lung, and brain.
- Evaluating ERP in metastatic sites is important for guiding therapy.
Purpose of the Study:
- To determine the prevalence of estrogen receptor protein in breast carcinoma metastases.
- To assess the response of ERP-positive versus ERP-negative metastases to endocrine ablation.
Main Methods:
- Performed estrogen receptor protein assays on 1,243 tissue specimens.
- Included 34 specimens from liver, lung, or brain metastases of primary breast carcinoma.
- Evaluated patient response to endocrine ablation based on ERP status.
Main Results:
- Eight of 34 metastatic specimens (23.5%) showed significant estrogen receptor protein.
- Four of five evaluable ERP-positive metastatic cases responded to endocrine ablation (80%).
- Two of 16 evaluable ERP-negative metastatic cases responded to endocrine ablation (12.5%).
Conclusions:
- Biopsy of liver and lung metastases can be diagnostically useful.
- Endocrine manipulation is an effective palliative strategy for ERP-positive metastases.
- ERP status in metastases guides the selection of endocrine therapy for improved patient outcomes.